IV CONNECTORS

FOR MULTIPLE FLEXBUMIN® CONTAINERS

Flexbumin 5%
[Albumin (Human)], USP, 5% Solution



Y-CONNECTOR SETS OFFERED BY TAKEDA

Delivered in the innovative GALAXY® shatterproof container, **FLEXBUMIN 5% [Albumin (Human)], USP, 5% Solution can be ordered with Y-connector sets at no additional charge.**[1,2]

- Y-connector sets **enable dual infusion** when large volumes of FLEXBUMIN 5% [Albumin (Human)] are required.[3]
- Y-connector sets are **compatible with infusion pump tubing spikes** and are suitable for gravity administration.[3]
- Five non-DEHP, non-latex Y-connector sets are included in each 10-bag case of FLEXBUMIN 5% when ordered using the Y-connector code.[4,5]

Caution: Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before the administration of fluid from the secondary container is complete.

Y-connector sets cannot be purchased separately from Takeda.

DEHP = diethylhexyl phthalate.

ORDERING INFORMATION

ORDERING CODE	CONCENTRATION/ SIZE	NDC NUMBER (BOX)	NDC NUMBER (BAG)	ALBUMIN/ CONTAINER (EQUIVALENT UNITS)	PACK FACTOR (CONTAINER DIMENSIONS)	SHIPPING WEIGHT
2G0250YC*	5%, 250 mL	0944-0495-05	0944-0495-06	12.5 g (1)	10 per case (12″ x 6″ x 6.25″)	7 lb

*Use this code to receive free Y-connector sets with your order (5 Y-connector sets per case).

CLICK HERE TO ORDER FLEXBUMIN

INDICATIONS AND LIMITATION OF USE

FLEXBUMIN 5% is indicated for hypovolemia, hypoalbuminemia (burns), and cardiopulmonary bypass surgery. Albumin is not indicated as an intravenous nutrient.

IMPORTANT SAFETY INFORMATION

Contraindications

- History of hypersensitivity reaction to albumin preparations or to any of the excipients (N-acetyltryptophan and sodium caprylate). Reactions have included anaphylactic shock, anaphylactic reaction, or hypersensitivity/allergic reactions.
- Severe anemia or cardiac failure with normal or increased intravascular volume.

Please see additional Important Safety Information throughout and click for Full Prescribing Information.

Flexbumin 5%
[Albumin (Human)],
USP, 5% Solution

ALTERNATIVES WITH MORE THAN TWO LEADS

Additional options may be available when administration requires more than two containers of FLEXBUMIN 5%.

The examples provided below are nonexhaustive and are provided for informational purposes only. Takeda does not recommend, validate, or guarantee any particular IV connector or transfer set. Always follow each device manufacturer's instructions before use and administration.



CHARTER MEDICAL

Available as 4-, 5-, 6-, or 10-lead harness sets with a port adapter or pooling bag[6]

To learn more about the Charter Medical lead harness sets, please contact Charter Medical customer support at 1-866-458-3116

IMPORTANT SAFETY INFORMATION, CONTINUED

Warnings and Precautions

Hypersensitivity Reactions: Have been observed (including anaphylactic reactions). If hypersensitivity reaction is suspected, discontinue administration immediately and implement appropriate standard medical treatment.

Hypervolemia/Hemodilution: Under conditions where hypervolemia and/or hemodilution may occur, adjust the dose and rate of infusion to the patient's volume status. When administering large volumes, monitor hemodynamic parameters. Ensure adequate substitution of other blood constituents and monitor electrolyte balance. Discontinue administration at the first clinical signs of cardiovascular overload.

Hemodynamics: Closely monitor hemodynamic parameters after administration for evidence of cardiac or respiratory failure, renal failure, or increasing intracranial pressure.

Blood Pressure: Monitor blood pressure in trauma patients and postoperative surgery patients in order to detect re-bleeding secondary to clot disruption.

Hemolysis: Do not dilute with Sterile Water for Injection, as there is potential risk of fatal hemolysis and acute renal failure in recipients.

Transmission of Infectious Agents: Because FLEXBUMIN 5% is made from human plasma, it may carry a risk of transmitting infectious agents (e.g., viruses, other pathogens). No cases of transmission of viral diseases, Creutzfeldt-Jakob disease (CJD) or variant Creutzfeldt-Jakob disease (vCJD) have ever been identified.

Adverse Reactions

The most serious adverse reactions are hypersensitivity reaction (including anaphylactic reaction) and pulmonary edema.

Administration Caution

Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before the administration of the fluid from the secondary container is complete.

Please see additional Important Safety Information throughout and click for Full Prescribing Information.

References: 1. FLEXBUMIN 5% [Albumin (Human)], USP, 5% Solution. Prescribing information. Takeda Pharmaceuticals U.S.A., Inc., 2023. **2.** Data on file. VV-MED-7455—FLEX-013 FLEXBUMIN biologics license application. **3.** Perucca R. Infusion therapy equipment: types of infusion therapy equipment. In: Hankins J, Lonsway RA, Hedrick C, Perdue MB, eds. *The Infusion Nurses Society Infusion Therapy in Clinical Practice*. 2nd ed. Philadelphia, PA: Saunders; 2001. **4.** CODAN. Product Catalog. Accessed August 1, 2024. https://www.codanusa.com/product-catalog/ **5.** US National Library of Medicine. Access GUDID: CODAN (10813153024741). Accessed August 1, 2024. https://accessgudid.nlm.nih.gov/devices/10813153024741 **6.** Charter Medical. Pooling harness sets. Accessed August 1, 2024. https://chartermedical.com/pooling-harness-sets/

Takeda